viewCreo Medical Group PLC

Commercial Launch of Speedboat at UEG Week

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:5.8pt;margin-bottom:.0001pt;text-align:justify;font-size:8.5pt;font-family:"Arial","sans-serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .bi{size:595.3pt 841.9pt;margin:2.0cm 42.55pt 2.0cm 42.55pt;}div.bi{}p.cr{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: center}span.cs{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.ct{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: justify}span.cn{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.cl{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.cv{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: center}span.ck{background:white} p.cw{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm}span.ci{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.cx{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-.1pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal}span.cg{color:black;background:white}span.be{}p.cy{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:14.05pt;margin-bottom: 0cm;margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify;line-height: normal}span.ce{color:black}span.cd{font-size:8.0pt;color:black}p.cz{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:14.05pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal}p.da{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 14.05pt; margin-top: 0cm; text-align: justify} p.db{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm}span.bz{font-size:9.0pt}p.dc{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}p.dd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; margin: 0cm; margin-bottom: .0001pt; text-align: justify}p.de{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: justify}table.df{margin-left:-5.4pt;border-collapse:collapse}td.bt{width:215.75pt;padding:0cm 5.4pt 0cm 5.4pt}p.dg{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: justify}td.br{width:272.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.dh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: right} p.di{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-.1pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:normal}p.dj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-.1pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height: normal}p.dk{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -.1pt; margin-top: 0cm; text-align: right; text-indent: -101.2pt}p.dl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}p.dm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-.1pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:normal}p.dn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-.1pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify}span.bk{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} /**/
RNS Number : 6700Q
Creo Medical Group PLC
22 October 2019

Creo Medical Group plc

("Creo" or the "Company")


Commercial Launch of Speedboat at UEG Week in Barcelona

Demonstration of wider suite of gastro-intestinal products awaiting regulatory clearance


Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces the full commercial launch of its Speedboat device, the first in a range of gastrointestinal ('GI') devices to be cleared for use with the CROMA Advanced Energy platform which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation.


Creo will be exhibiting at the United European Gastroenterology ('UEG') Week Congress in Barcelona from 21-23, October 2019 show-casing the CROMA Platform, powered by its unique full spectrum adaptive technology along with the GI suite of products for the dissection, resection, haemostasis and ablation of soft tissue. These products enable a wide variety of procedures, all of which are targeting treatment in the endoscopy room instead of the operating theatre wherever possible. This will be the first time the suite of products will have been fully demonstrated to the market as plans are put in place for first human cases.


Haemostasis device (HS1)* - is the ONLY non-stick haemostasis device in any sphere of therapy which builds on the excellent results seen clinically with the Speedboat device.


Resection device (RG1)* - is the ONLY bipolar RF scissors device in any sphere of therapy powered by the unique full spectrum adaptive technology in the CROMA platform. With capability to simultaneously utilise RF and Microwave energy this device truly brings laparoscopic surgical capability into the world of flexible endoscopic surgery.


Narrow Probe ablation needle (NP1)* - is the SMALLEST microwave ablation device in any sphere of therapy, providing precise and accurate delivery of microwave energy for ablation of soft tissue in various tissue types, ideal for the management of various GI disease states


*internal nomenclature


The commercial launch of the CROMA platform and Speedboat, along with the unveiling of a suite of devices at UEG Week is a major milestone for the Company and comes as a growing number of GI Endoscopists in the UK, mainland Europe, the US and South Africa have successfully completed training via the Clinical Education Programme and have now performed multiple successful procedures, removing lesions in both upper and lower GI cases using the device. The first commercial orders for Speedboat were announced in June this year.


UEG Week is a great opportunity for researchers and companies to present new research across a range of digestive disease areas and combines world class scientific research, invited lectures by leaders in gastroenterology and cutting-edge post-graduate teaching sessions to cover topics to interest the entire GI community.


The event is organised by the UEG Society and will take place at Fira Barcelona Gran Via, Barcelona, Catalonia, Spain. Creo Medical will be exhibiting at booth 46 throughout the event.


Craig Gulliford, Chief Executive Officer, commented:

"The full commercial launch of the Speedboat device, coupled with the opportunity to show-case the wider suite of products at this key event, is another important step for the Company.  In addition to the profiling of our technology in the exhibition area, we will also be using the time together with our distribution partners throughout Europe to outline the initial roll out plans for the wider portfolio and use this fantastic opportunity to build further excitement and momentum as we head into 2020."



Creo Medical Group plc


Richard Rees (CFO)

+44 (0)1291 606 005



Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys / Cameron MacRitchie (NOMAD)


Michael Johnson / Russell Kerr (Sales)




Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238



About Creo Medical


Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.


The Company's strategy is to bring its CROMA platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.


For more information about Creo Medical please see our website, investors.creomedical.com



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Creo Medical Group PLC

Price: 177.5

Market: LSE
Market Cap: £266.92 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...